Cargando…
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
Autores principales: | Maura, F, Guidetti, A, Pellegrinelli, A, Dodero, A, Pennisi, M, Caprioli, C, Testi, A, Farina, L, Bolli, N, Devizzi, L F, Cabras, A, Corradini, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380909/ https://www.ncbi.nlm.nih.gov/pubmed/28304403 http://dx.doi.org/10.1038/bcj.2017.25 |
Ejemplares similares
-
P1188: PERSONALIZED TREATMENT ACCORDING TO BIOLOGICAL PROFILE IMPROVES OUTCOME OF NEWLY DIAGNOSED PATIENTS AFFECTED BY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE EXPERIENCE
por: Guidetti, A., et al.
Publicado: (2022) -
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
por: Dodero, A., et al.
Publicado: (2019) -
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021) -
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
Publicado: (2016) -
P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS.
por: Dodero, A., et al.
Publicado: (2022)